ADMINSQ
DEAD

Serial Number

97690361

Owner

BRISTOL-MYERS SQUIBB COMPANY

Attorney

Marilyn F. Kelly

Filing Date

Nov 23, 2022

Add to watchlist:

No watchlists yet
View on USPTO

ADMINSQ Trademark

Serial Number: 97690361

ADMINSQ is a trademark filed by BRISTOL-MYERS SQUIBB COMPANY on November 23, 2022. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

BRISTOL-MYERS SQUIBB COMPANY (4,799 trademarks)

NEW YORK, NY 10154

Entity Type: 03

Trademark Details

Filing Date

November 23, 2022

Registration Date

Not Registered

Published for Opposition

October 3, 2023

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Jul 12, 2024 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Jul 1, 2024 ABN6
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 28, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 3, 2023 NPUB
PUBLISHED FOR OPPOSITION
Oct 3, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 13, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 28, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 25, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 24, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 24, 2023 TROA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 2, 2023 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Aug 2, 2023 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Aug 2, 2023 COAR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 24, 2023 GNRN
NON-FINAL ACTION E-MAILED
May 24, 2023 GNRT
NON-FINAL ACTION WRITTEN
May 24, 2023 CNRT
ASSIGNED TO EXAMINER
May 15, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 28, 2022 NWOS
NEW APPLICATION ENTERED
Nov 26, 2022 NWAP